

Correspondence to Dr Bongani M Mayosi, Department of Medicine, J Floor Old Groote Schuur Hospital, Anzio Road, Observatory, 7925, Cape Town, South Africa; bongani.mayosi@uct.ac.za

Contributors The idea of the study was conceived by BMM and EDS. BMM, EDS, MN, KAW and RJW were involved in the design of the experiment. The experimental work was carried out by MN, KM and JW. MB conducted the statistical analysis of the data. MN wrote the first draft of the manuscript, and all authors participated in the finalisation of the manuscript.

Funding This work was supported by the Wellcome Trust of Great Britain (references 084323, 088316, 083226). Additional support was provided by the Medical Research Councils of the UK and South Africa and the Lily and Hausmann Research Trust.

Competing interests None.

Patient consent Obtained.

Ethics approval University of Cape Town Human Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Normal pericardial fluid and pericardial fluid infected with *Mycobacterium tuberculosis* is available for the participants in this study. These biological materials are owned by the IMPI Registry Investigators. Investigators may propose sub-studies based on the biological material to the IMPI Registry Steering Committee.

Published Online First 26 July 2012



This paper is freely available online under the BMJ Journals unlocked scheme, see <http://heart.bmj.com/site/about/unlocked.xhtml>.

Heart 2012;**98**:1326–1328.
doi:10.1136/heartjnl-2012-302196

REFERENCES

1. **Imazio M**, Brucato A, Maestroni S, *et al*. Risk of constrictive pericarditis after Acute pericarditis. *Circulation* 2011;**124**:1270–5.
2. **Castoldi G**, di Gioia CR, Bombardi C, *et al*. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. *Clin Sci (Lond)* 2009;**118**:211–20.
3. **Henderson NC**, Mackinnon AC, Farnworth SL, *et al*. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. *Am J Pathol* 2008;**172**:288–98.
4. **Liu YH**, D'Ambrosio M, Liao TD, *et al*. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. *Am J Physiol Heart Circ Physiol* 2009; **296**:H404–12.
5. **Cavasin MA**, Liao TD, Yang XP, *et al*. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. *Hypertension* 2007;**50**:130–6.

RETRACTION: NOTICE OF UNRELIABLE FINDINGS

doi:10.1136/heartjnl-2011-301101ret

Piccolo R, L Gu Y L, Iversen A Z, Dominguez-Rodriguez A, De Smet B J G L, Mahmoud K D, Eitel I, Abreu-Gonzalez P, Thiele H, Piscione F. Clinical impact of intracoronary abciximab in patients undergoing primary percutaneous coronary intervention: an individual patient-data pooled analysis of randomised studies. *Heart* 2012 May 24 [Epub ahead of print] doi:10.1136/heartjnl-2011-301101. The findings in this paper are unreliable because it fails to address the data from AIDA STEMI [*Lancet* 2012;**379**:923–31], to which the authors had access prior to submission and which contraindicate the paper's conclusion by showing no advantage for intracoronary administration. The authors were asked to update the paper to include the AIDA STEMI findings but, with the exception of Dr Olivier F Bertrand, they declined. Owing to this difference of opinion, Dr Bertrand asked to be removed from the list of authors, a request to which we acceded. Under these circumstances, the matter was considered by COPE who recommended retraction and this paper has now been withdrawn from *Heart*.

Correspondence to Dr Bongani M Mayosi, Department of Medicine, J Floor Old Groote Schuur Hospital, Anzio Road, Observatory, 7925, Cape Town, South Africa; bongani.mayosi@uct.ac.za

Contributors The idea of the study was conceived by BMM and EDS. BMM, EDS, MN, KAW and RJW were involved in the design of the experiment. The experimental work was carried out by MN, KM and JW. MB conducted the statistical analysis of the data. MN wrote the first draft of the manuscript, and all authors participated in the finalisation of the manuscript.

Funding This work was supported by the Wellcome Trust of Great Britain (references 084323, 088316, 083226). Additional support was provided by the Medical Research Councils of the UK and South Africa and the Lily and Hausmann Research Trust.

Competing interests None.

Patient consent Obtained.

Ethics approval University of Cape Town Human Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Normal pericardial fluid and pericardial fluid infected with *Mycobacterium tuberculosis* is available for the participants in this study. These biological materials are owned by the IMPI Registry Investigators. Investigators may propose sub-studies based on the biological material to the IMPI Registry Steering Committee.

Published Online First 26 July 2012



This paper is freely available online under the BMJ Journals unlocked scheme, see <http://heart.bmj.com/site/about/unlocked.xhtml>.

Heart 2012;**98**:1326–1328.
doi:10.1136/heartjnl-2012-302196

REFERENCES

1. **Imazio M**, Brucato A, Maestroni S, *et al*. Risk of constrictive pericarditis after Acute pericarditis. *Circulation* 2011;**124**:1270–5.
2. **Castoldi G**, di Gioia CR, Bombardi C, *et al*. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. *Clin Sci (Lond)* 2009;**118**:211–20.
3. **Henderson NC**, Mackinnon AC, Farnworth SL, *et al*. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. *Am J Pathol* 2008;**172**:288–98.
4. **Liu YH**, D'Ambrosio M, Liao TD, *et al*. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. *Am J Physiol Heart Circ Physiol* 2009; **296**:H404–12.
5. **Cavasin MA**, Liao TD, Yang XP, *et al*. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. *Hypertension* 2007;**50**:130–6.

RETRACTION: NOTICE OF UNRELIABLE FINDINGS

doi:10.1136/heartjnl-2011-301101ret

Piccolo R, L Gu Y L, Iversen A Z, Dominguez-Rodriguez A, De Smet B J G L, Mahmoud K D, Eitel I, Abreu-Gonzalez P, Thiele H, Piscione F. Clinical impact of intracoronary abciximab in patients undergoing primary percutaneous coronary intervention: an individual patient-data pooled analysis of randomised studies. *Heart* 2012 May 24 [Epub ahead of print] doi:10.1136/heartjnl-2011-301101. The findings in this paper are unreliable because it fails to address the data from AIDA STEMI [*Lancet* 2012;**379**:923–31], to which the authors had access prior to submission and which contraindicate the paper's conclusion by showing no advantage for intracoronary administration. The authors were asked to update the paper to include the AIDA STEMI findings but, with the exception of Dr Olivier F Bertrand, they declined. Owing to this difference of opinion, Dr Bertrand asked to be removed from the list of authors, a request to which we acceded. Under these circumstances, the matter was considered by COPE who recommended retraction and this paper has now been withdrawn from *Heart*.